Conditions: Metastatic Breast Cancer
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 120
Healthy volunteers: no

Brief summary:
The purpose of this study is to find out what effect the combination of letrozole (brand name: Femara) and dasatinib (brand name: Sprycel) has on metastatic breast cancer compared to letrozole alone

Detailed description:

Arms:
arm 1: None arm 2: None

Interventions: intervention 1: Dasatinib intervention 2: Letrozole
Intervention descriptions: intervention 1: Tablets, Oral, 100 mg once daily, up to 2 years intervention 2: Tablets, Oral, 2.5 mg, once daily, up to 2 years

Protocol document: